Literature DB >> 27292599

Irreversible Electroporation for Surgical Renal Masses in Solitary Kidneys: Short-Term Interventional and Functional Outcome.

Steffen J Diehl1, Nils Rathmann2, Michael Kostrzewa1, Manuel Ritter3, Arman Smakic1, Stefan O Schoenberg1, Maximilian C Kriegmair3.   

Abstract

PURPOSE: To examine short-term outcomes and complications in patients with a solitary kidney treated with irreversible electroporation (IRE) for a potentially malignant renal mass.
MATERIALS AND METHODS: Five patients (2 female, 3 male; mean age, 66 y) with 7 lesions who underwent IRE for renal tumors in a solitary kidney between August 2014 and August 2015 were retrospectively reviewed. Changes in signal intensity (SI) of the treated lesion were evaluated on contrast-enhanced magnetic resonance imaging. To evaluate functional outcome, creatinine levels and estimated glomerular filtration rate (eGFR) were compared vs baseline after 1 day, 2-7 days, 3-6 weeks, and 6-12 weeks after the intervention.
RESULTS: Mean tumor diameter was 24.4 mm (range, 15-38 mm), with an average score of 7.7 (range, 4-9) per R.E.N.A.L. criteria (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines). There was a progressive, significant decrease in treated tumor SI on follow-up imaging (mean, 70%-82%), suggesting a treatment response rate of 100% at a mean follow-up of 6.4 months (range, 3-11 mo). Two minor acute complications (Society of Interventional Radiology class A) occurred: transient gross hematuria and stage I acute kidney failure. Overall, there was no significant decrease in eGFR (-2.75 mL/min) over 3 months, even though 1 patient's eGFR decreased from > 60 mL/min/1.73m(2) to 44 mL/min/1.73m(2).
CONCLUSIONS: The data suggest that percutaneous IRE for renal mass in patients with a solitary kidney is safe and feasible. It may help to preserve renal function and offers promising short-term oncologic results.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27292599     DOI: 10.1016/j.jvir.2016.03.044

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  12 in total

Review 1.  Developing a Roadmap for Interventional Oncology.

Authors:  Stefan O Schoenberg; Ulrike I Attenberger; Stephen B Solomon; Ralph Weissleder
Journal:  Oncologist       Date:  2018-06-29

2.  Percutaneous irreversible electroporation for the treatment of small renal masses: The first Canadian case series.

Authors:  Bonnie Liu; Jordyn Clark; Trustin Domes; Chris Wall; Kunal Jana
Journal:  Can Urol Assoc J       Date:  2019-01-21       Impact factor: 1.862

3.  Irreversible electroporation of small renal masses: suboptimal oncologic efficacy in an early series.

Authors:  Noah E Canvasser; Igor Sorokin; Aaron H Lay; Monica S C Morgan; Asim Ozayar; Clayton Trimmer; Jeffrey A Cadeddu
Journal:  World J Urol       Date:  2017-03-02       Impact factor: 4.226

Review 4.  [Ablative therapy of small renal masses].

Authors:  M C Kriegmair; N Wagener; S J Diehl; N Rathmann
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

Review 5.  [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].

Authors:  P Wiggermann; K Brünn; W Bäumler
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

Review 6.  Available ablation energies to treat cT1 renal cell cancer: emerging technologies.

Authors:  P J Zondervan; M Buijs; D M De Bruin; O M van Delden; K P Van Lienden
Journal:  World J Urol       Date:  2018-11-17       Impact factor: 4.226

7.  A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety.

Authors:  Ziyin Wang; Jian Lu; Wei Huang; Zhiyuan Wu; Ju Gong; Qingbing Wang; Qin Liu; Cangyi Wang; Yu Zhu; Xiaoyi Ding; Zhongmin Wang
Journal:  BMC Cancer       Date:  2021-02-05       Impact factor: 4.430

8.  Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience.

Authors:  Tze Min Wah; James Lenton; Jonathan Smith; Paul Bassett; Satinder Jagdev; Christy Ralph; Naveen Vasudev; Selina Bhattarai; Michael Kimuli; Jon Cartledge
Journal:  Eur Radiol       Date:  2021-03-30       Impact factor: 5.315

9.  Elimination of Purkinje Fibers by Electroporation Reduces Ventricular Fibrillation Vulnerability.

Authors:  Christopher Livia; Alan Sugrue; Tyra Witt; Murray D Polkinghorne; Elad Maor; Suraj Kapa; Helge I Lehmann; Christopher V DeSimone; Atta Behfar; Samuel J Asirvatham; Christopher J McLeod
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

10.  Frailty predicts outcome of partial nephrectomy and guides treatment decision towards active surveillance and tumor ablation.

Authors:  M T Walach; M F Wunderle; N Haertel; J K Mühlbauer; K F Kowalewski; N Wagener; N Rathmann; M C Kriegmair
Journal:  World J Urol       Date:  2021-01-30       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.